Host-directed therapy against mycobacterium tuberculosis infections with diabetes mellitus
Tuberculosis (TB) is caused by the bacterial pathogen Mycobacterium tuberculosis (MTB) and is one of the principal reasons for mortality and morbidity worldwide. Currently, recommended anti-tuberculosis drugs include isoniazid, rifampicin, ethambutol, and pyrazinamide. TB treatment is lengthy and in...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2024-01-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1305325/full |
| _version_ | 1797362465342750720 |
|---|---|
| author | Li Zhao Ke Fan Xuezhi Sun Wei Li Fenfen Qin Liwen Shi Feng Gao Chunlan Zheng |
| author_facet | Li Zhao Ke Fan Xuezhi Sun Wei Li Fenfen Qin Liwen Shi Feng Gao Chunlan Zheng |
| author_sort | Li Zhao |
| collection | DOAJ |
| description | Tuberculosis (TB) is caused by the bacterial pathogen Mycobacterium tuberculosis (MTB) and is one of the principal reasons for mortality and morbidity worldwide. Currently, recommended anti-tuberculosis drugs include isoniazid, rifampicin, ethambutol, and pyrazinamide. TB treatment is lengthy and inflicted with severe side-effects, including reduced patient compliance with treatment and promotion of drug-resistant strains. TB is also prone to other concomitant diseases such as diabetes and HIV. These drug-resistant and complex co-morbid characteristics increase the complexity of treating MTB. Host-directed therapy (HDT), which effectively eliminates MTB and minimizes inflammatory tissue damage, primarily by targeting the immune system, is currently an attractive complementary approach. The drugs used for HDT are repositioned drugs in actual clinical practice with relative safety and efficacy assurance. HDT is a potentially effective therapeutic intervention for the treatment of MTB and diabetic MTB, and can compensate for the shortcomings of current TB therapies, including the reduction of drug resistance and modulation of immune response. Here, we summarize the state-of-the-art roles and mechanisms of HDT in immune modulation and treatment of MTB, with a special focus on the role of HDT in diabetic MTB, to emphasize the potential of HDT in controlling MTB infection. |
| first_indexed | 2024-03-08T16:07:21Z |
| format | Article |
| id | doaj.art-5a2dd72b7e4144e4a661feb5d0ae95b8 |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-03-08T16:07:21Z |
| publishDate | 2024-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-5a2dd72b7e4144e4a661feb5d0ae95b82024-01-08T04:44:54ZengFrontiers Media S.A.Frontiers in Immunology1664-32242024-01-011410.3389/fimmu.2023.13053251305325Host-directed therapy against mycobacterium tuberculosis infections with diabetes mellitusLi Zhao0Ke Fan1Xuezhi Sun2Wei Li3Fenfen Qin4Liwen Shi5Feng Gao6Chunlan Zheng7Department of Tuberculosis III, Wuhan Pulmonary Hospital, Wuhan, Hubei, ChinaDepartment of Tuberculosis III, Wuhan Pulmonary Hospital, Wuhan, Hubei, ChinaDepartment of Tuberculosis III, Wuhan Pulmonary Hospital, Wuhan, Hubei, ChinaDepartment of Tuberculosis III, Wuhan Pulmonary Hospital, Wuhan, Hubei, ChinaDepartment of Tuberculosis III, Wuhan Pulmonary Hospital, Wuhan, Hubei, ChinaDepartment of Tuberculosis III, Wuhan Pulmonary Hospital, Wuhan, Hubei, ChinaDepartment of Endocrinology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, ChinaDepartment of Tuberculosis III, Wuhan Pulmonary Hospital, Wuhan, Hubei, ChinaTuberculosis (TB) is caused by the bacterial pathogen Mycobacterium tuberculosis (MTB) and is one of the principal reasons for mortality and morbidity worldwide. Currently, recommended anti-tuberculosis drugs include isoniazid, rifampicin, ethambutol, and pyrazinamide. TB treatment is lengthy and inflicted with severe side-effects, including reduced patient compliance with treatment and promotion of drug-resistant strains. TB is also prone to other concomitant diseases such as diabetes and HIV. These drug-resistant and complex co-morbid characteristics increase the complexity of treating MTB. Host-directed therapy (HDT), which effectively eliminates MTB and minimizes inflammatory tissue damage, primarily by targeting the immune system, is currently an attractive complementary approach. The drugs used for HDT are repositioned drugs in actual clinical practice with relative safety and efficacy assurance. HDT is a potentially effective therapeutic intervention for the treatment of MTB and diabetic MTB, and can compensate for the shortcomings of current TB therapies, including the reduction of drug resistance and modulation of immune response. Here, we summarize the state-of-the-art roles and mechanisms of HDT in immune modulation and treatment of MTB, with a special focus on the role of HDT in diabetic MTB, to emphasize the potential of HDT in controlling MTB infection.https://www.frontiersin.org/articles/10.3389/fimmu.2023.1305325/fullmycobacterium tuberculosisdiabetes mellitushost-directed therapydrug-resistanceimmune |
| spellingShingle | Li Zhao Ke Fan Xuezhi Sun Wei Li Fenfen Qin Liwen Shi Feng Gao Chunlan Zheng Host-directed therapy against mycobacterium tuberculosis infections with diabetes mellitus Frontiers in Immunology mycobacterium tuberculosis diabetes mellitus host-directed therapy drug-resistance immune |
| title | Host-directed therapy against mycobacterium tuberculosis infections with diabetes mellitus |
| title_full | Host-directed therapy against mycobacterium tuberculosis infections with diabetes mellitus |
| title_fullStr | Host-directed therapy against mycobacterium tuberculosis infections with diabetes mellitus |
| title_full_unstemmed | Host-directed therapy against mycobacterium tuberculosis infections with diabetes mellitus |
| title_short | Host-directed therapy against mycobacterium tuberculosis infections with diabetes mellitus |
| title_sort | host directed therapy against mycobacterium tuberculosis infections with diabetes mellitus |
| topic | mycobacterium tuberculosis diabetes mellitus host-directed therapy drug-resistance immune |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1305325/full |
| work_keys_str_mv | AT lizhao hostdirectedtherapyagainstmycobacteriumtuberculosisinfectionswithdiabetesmellitus AT kefan hostdirectedtherapyagainstmycobacteriumtuberculosisinfectionswithdiabetesmellitus AT xuezhisun hostdirectedtherapyagainstmycobacteriumtuberculosisinfectionswithdiabetesmellitus AT weili hostdirectedtherapyagainstmycobacteriumtuberculosisinfectionswithdiabetesmellitus AT fenfenqin hostdirectedtherapyagainstmycobacteriumtuberculosisinfectionswithdiabetesmellitus AT liwenshi hostdirectedtherapyagainstmycobacteriumtuberculosisinfectionswithdiabetesmellitus AT fenggao hostdirectedtherapyagainstmycobacteriumtuberculosisinfectionswithdiabetesmellitus AT chunlanzheng hostdirectedtherapyagainstmycobacteriumtuberculosisinfectionswithdiabetesmellitus |